StockNews.AI
CRDF
StockNews.AI
180 days

Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update

1. CRDF announced a Q4 2024 financial call on Feb 27 after trading. 2. The call will review clinical and financial results from Q4 2024. 3. CRDF advances its PLK1 inhibitor onvansertib in multiple cancer trials. 4. Investors can access the webcast via the company website.

4m saved
Insight
Article

FAQ

Why Neutral?

This announcement is a scheduled earnings call without new data. Historical earnings calls have induced short-term volatility but typically no sustained directional move absent surprises.

How important is it?

Earnings calls are key events for biotech firms. While the scheduled call is standard, new clinical results could be material, hence a moderate impact rating.

Why Short Term?

Earnings call events typically affect stock price immediately after disclosure. Like other biotech earnings releases, any unexpected results could cause short-term price swings.

Related Companies

SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that it will hold a conference call on Thursday, February 27 after the close of trading to review financial results for the fourth quarter ended December 31, 2024. Conference Call and Webcast Cardiff Oncology will host a conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT on February 27, 2025. Individuals interested in listening to the live conference call may do so by using the webcast link in the "Investors" section of the company's website at https://investors.cardiffoncology.com/news-events/events. A replay will be available in the investor relations section on the company's website following the completion of the call. About Cardiff Oncology, Inc. Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard of care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC), as well as in ongoing and planned investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC) and triple negative breast cancer (TNBC). These programs and the Company's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit https://www.cardiffoncology.com. Cardiff Oncology Contact: James LevineChief Financial Officer858-952-7670jlevine@cardiffoncology.com Investor Contact:Kiki Patel, PharmDGilmartin Group332-895-3225Kiki@gilmartinir.com Media Contact:Grace SpencerTaft Communications609-583-1151grace@taftcommunications.com

Related News